Evidence map›Paper›PMID 41674660›Full record

ReviewGenes & diseases2026

YTHDF2 in inflammation: Mechanisms and therapeutic strategies.

Junxiu Liu, Senxu Lu, Chuanhuai Chen, Xiaobo Lin, Lijuan Xia, Pansheng Xu, Jinjin Shao, Luxi Yang, Wenhai Huang, Lijiang Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Junxiu LiuZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, Zhejiang 310053, China.
Senxu LuDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
Chuanhuai ChenZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, Zhejiang 310053, China.
Xiaobo LinZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, Zhejiang 310053, China.
Lijuan XiaZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, Zhejiang 310053, China.
Pansheng XuZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, Zhejiang 310053, China.
Jinjin ShaoZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, Zhejiang 310053, China.
Luxi YangZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, Zhejiang 310053, China.
Wenhai HuangZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, Zhejiang 310053, China.
Lijiang ZhangZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, Zhejiang 310053, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation is a double-edged sword in biology. Moderate immune responses effectively eliminate pathogens and promote tissue repair, while excessive or persistent inflammation drives acute and chronic diseases. N6-methyladenosine (m

Indexed as

InflammationN6-methyladenosineRNA modificationTherapeutic drugsYTHDF2

Identifiers

PMID41674660
PMCPMC12886528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.